ArticleSurgery today2026
SARS-CoV-2 infection in lung transplant recipients: a single-center retrospective study in Japan.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLung transplant (LTx) recipients are at a higher risk of infection and mortality due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The course of coronavirus disease 2019 (COVID-19) in Japanese LTx recipients remains unknown. This study aimed to clarify the incidence, outcomes, and clinical characteristics of COVID-19 in LTx recipients in Japan over a 3-year period.
methodsThis single-center retrospective study enrolled all LTx recipients who underwent LTx at Kyoto University Hospital between June 2008 and December 2022 and who were followed up during the COVID-19 pandemic from March 2020 to June 2023.
resultsAmong 230 LTx recipients, 64 (27.8%) developed SARS-CoV-2 infection and one (1.6%) died due to COVID-19. No significant differences in baseline characteristics, except for hypertension, were observed between the LTx recipients with and without COVID-19. Disease severity decreased as variants of concern transitioned but remained high even after 2022. Unilateral LTx, advanced age, and diabetes mellitus were associated with COVID-19 severity.
conclusionsThe incidence of COVID-19 in LTx recipients was similar to that in the general Japanese population, whereas the disease severity in LTx recipients remained high even after the Omicron era. Continuous development of preventive and early therapeutic interventions is required for these vulnerable groups.
Indexed as
Identifiers
41003720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.